207 related articles for article (PubMed ID: 35858980)
1. Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice.
West EG; McDermott C; Chess-Williams R; Sellers DJ
Sci Rep; 2022 Jul; 12(1):12365. PubMed ID: 35858980
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment with a β
Imamura T; Ogawa T; Minagawa T; Nagai T; Suzuki T; Saito T; Yokoyama H; Nakazawa M; Ishizuka O
Neurourol Urodyn; 2017 Apr; 36(4):1026-1033. PubMed ID: 27367573
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
Vecchioli Scaldazza C; Morosetti C
Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
[TBL] [Abstract][Full Text] [Related]
7. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
Soliman MG; El-Abd S; El-Gamal OM; Raheem AA; Abou-Ramadan AR; El-Abd AS
Urol Int; 2021; 105(11-12):1011-1017. PubMed ID: 34010843
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
9. Cold stress-induced bladder overactivity in type 2 diabetic mellitus rats is mitigated by the combination of a M
Hara H; Imamura T; Suzuki A; Ueno M; Minagawa T; Ogawa T; Ishizuka O
Low Urin Tract Symptoms; 2023 Mar; 15(2):68-75. PubMed ID: 36543093
[TBL] [Abstract][Full Text] [Related]
10. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
Gibson W; MacDiarmid S; Huang M; Siddiqui E; Stölzel M; Choudhury N; Drake MJ
Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study.
Kim SC; Park M; Chae C; Yoon JH; Kwon T; Park S; Moon KH; Cheon SH; Park S
Investig Clin Urol; 2021 May; 62(3):317-323. PubMed ID: 33834641
[TBL] [Abstract][Full Text] [Related]
14. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients.
Robinson D; Kelleher C; Staskin D; Mueller ER; Falconer C; Wang J; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Hakimi Z; Herschorn S
Neurourol Urodyn; 2018 Jan; 37(1):394-406. PubMed ID: 28704584
[TBL] [Abstract][Full Text] [Related]
16. Mirabegron causes vesical and urethral relaxation in rats with spinal cord injury.
Sugaya K; Nishijima S; Kadekawa K; Noguchi K; Ueda T; Yamamoto H
Low Urin Tract Symptoms; 2020 Jan; 12(1):92-98. PubMed ID: 31389202
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J
Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884
[TBL] [Abstract][Full Text] [Related]
18. Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial.
Hsiao SM; Tu FC; Su TC; Wu PC; Lin HH
Sci Rep; 2022 Aug; 12(1):14219. PubMed ID: 35987885
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study.
Mueller ER; van Maanen R; Chapple C; Abrams P; Herschorn S; Robinson D; Stoelzel M; Yoon SJ; Al-Shukri S; Rechberger T; Gratzke C
Neurourol Urodyn; 2019 Feb; 38(2):779-792. PubMed ID: 30644570
[TBL] [Abstract][Full Text] [Related]
20. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron.
Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
Arch Gerontol Geriatr; 2015; 61(2):212-6. PubMed ID: 26169181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
